Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1654 for prevention of RSV in pre-term and full-term infants
2022-500350-42-01Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing MK-1654 with Placebo (2 arms). Primary endpoints: RSV-associated MALRI incidence, Solicited injection-site adverse events and 6 more. Started Nov 2022; status: completed.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2022-500350-42-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500350-42-01.